Rep. Chris Collins (R-N.Y.) was indicted Wednesday on federal insider trading charges. Prosecutors alleged that he used information he received while on the board of an Australian biotechnology firm, Innate Immunotherapeutics, to tip off his son and others to sell the company’s stock before a damaging report on the company’s lack of success with a drug to treat multiple sclerosis.
The Associated Press has a story about the indictment and the complaint filed by the Securities and Exchange Commission.
Here’s a look at Kaiser Health News’ earlier coverage of Collins’ relationship with the company:
GOP Congressman Chris Collins Indicted On Insider Trading Charges
We encourage organizations to republish our content, free of charge. Here’s what we ask:
You must credit us as the original publisher, with a hyperlink to our khn.org site. If possible, please include the original author(s) and “Kaiser Health News” in the byline. Please preserve the hyperlinks in the story.
It’s important to note, not everything on khn.org is available for republishing. If a story is labeled “All Rights Reserved,” we cannot grant permission to republish that item.